Beacon Investment Advisory Services Inc. Has $1.38 Million Holdings in The Cooper Companies, Inc. $COO

Beacon Investment Advisory Services Inc. boosted its position in The Cooper Companies, Inc. (NASDAQ:COO) by 96.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 19,227 shares of the medical device company’s stock after acquiring an additional 9,434 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Cooper Companies were worth $1,379,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of COO. Root Financial Partners LLC lifted its position in Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after acquiring an additional 162 shares during the last quarter. Avalon Trust Co acquired a new stake in shares of Cooper Companies in the second quarter valued at about $25,000. SJS Investment Consulting Inc. grew its position in shares of Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares during the last quarter. Elevation Wealth Partners LLC increased its stake in shares of Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after purchasing an additional 375 shares during the period. Finally, Continuum Advisory LLC bought a new position in shares of Cooper Companies in the second quarter worth about $30,000. Institutional investors own 24.39% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on COO shares. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a research report on Friday, June 5th. JPMorgan Chase & Co. lowered their target price on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a report on Friday, June 5th. Mizuho set a $85.00 price target on Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Needham & Company LLC cut their price target on Cooper Companies from $101.00 to $86.00 and set a “buy” rating for the company in a report on Friday, June 5th. Finally, Piper Sandler set a $86.00 price objective on Cooper Companies and gave the company an “overweight” rating in a research report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $81.64.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal Q3 non-GAAP EPS of $1.15, exceeding the $1.11-$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while GAAP EPS was $2.24, helped by a $307.2 million discrete tax benefit from the favorable completion of a U.K. tax examination. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: Cash generation and capital returns were strong: free cash flow increased 66% to $273 million, and the company repurchased $339.1 million of stock during the quarter. The board also expanded its share-repurchase authorization from $2 billion to $3 billion. CooperCompanies Completes Strategic Review
• Neutral Sentiment: CooperSurgical revenue rose 2% on a reported basis and 3% organically, but CooperVision revenue was unchanged year over year. Overall quarterly revenue growth was only about 1% and fell short of the roughly $1.10 billion consensus estimate.
• Negative Sentiment: Management guided fiscal 2026 non-GAAP EPS to $4.51-$4.55, below the $4.63 analyst consensus, with revenue guidance of $4.229-$4.252 billion. Fourth-quarter EPS guidance of $1.05-$1.09 was also well below the approximately $1.20 expected by analysts. The Cooper Companies Q3 Earnings Metrics
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because received offers were not sufficiently attractive. Investors may view this as a missed opportunity to unlock value, particularly amid valuation pressure from a new non-hormonal IUD competitor and fertility-related litigation costs. CooperCompanies Strategic Review and Buyback

Cooper Companies Stock Down 6.2%

COO stock opened at $63.48 on Thursday. The Cooper Companies, Inc. has a twelve month low of $58.89 and a twelve month high of $89.83. The company has a market cap of $12.38 billion, a PE ratio of 53.80, a price-to-earnings-growth ratio of 1.77 and a beta of 0.82. The business’s 50-day simple moving average is $72.42 and its 200 day simple moving average is $70.02. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, research analysts anticipate that The Cooper Companies, Inc. will post 4.63 earnings per share for the current year.

Cooper Companies declared that its Board of Directors has approved a stock repurchase program on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.